Intradermal inoculations of low doses of Leishmania major and Leishmania amazonensis metacyclic promastigotes induce different immunoparasitic processes and status of protection in BALB/c mice

Courret, Nathalie; Lang, Thierry; Milon, Geneviève; Antoine, Jean Claude

doi:10.1016/s0020-7519(03)00179-6

Cited by 42 publications

(38 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These mice are susceptible to infection by various Leishmania species, including L. major and L. amazonensis as presented here (7,17). The standard method for following infection in this in vivo model is based on estimation of parasite loads by labor-intensive microscopic enumeration of sacrificed animals or caliper-based measurements of the size or thickness of lesions that have developed at the site of infection, such as the footpad, ear dermis, or tail base (7,22).…”

mentioning

confidence: 88%

Real-Time In Vivo Green Fluorescent Protein Imaging of a Murine Leishmaniasis Model as a New Tool for Leishmania Vaccine and Drug Discovery

Mehta

Huang

Yang

et al. 2008

Clin Vaccine Immunol

View full text Add to dashboard Cite

Leishmania species are obligate intracellular protozoan parasites that cause a broad spectrum of clinical diseases in mammalian hosts. The most frequently used approach to quantify parasites in murine model systems is based on thickness measurements of the footpad or ear after experimental infection. To overcome the limitations of this method, we used a Leishmania mutant episomally transfected with enhanced green fluorescent protein, enabling in vivo real-time whole-body fluorescence imaging, to follow the progression of Leishmania infection in parasitized tissues. Fluorescence correlated with the number of Leishmania parasites in the tissue and demonstrated the real-time efficacy of a therapeutic vaccine. This approach provides several substantial advantages over currently available animal model systems for the in vivo study of immunopathogenesis, prevention, and therapy of leishmaniasis. These include improvements in sensitivity and the ability to acquire real-time data on progression and spread of the infection.

show abstract

mentioning

confidence: 88%

Real-Time In Vivo Green Fluorescent Protein Imaging of a Murine Leishmaniasis Model as a New Tool for Leishmania Vaccine and Drug Discovery

Mehta

Huang

Yang

et al. 2008

Clin Vaccine Immunol

View full text Add to dashboard Cite

show abstract

“…Although leishmaniasis is an intracellular infection, the contribution of CD8 + T-cells as immune correlates of disease at primary infection remained to be addressed [28,29] until the data from low dose experimental challenge in both Balb/c and C57BL/6 mice was extrapolated. The data from Balb/c mice infected by low dose challenge was controversially CD8 + T-cell dependent, but these mice were able to elevate Th1 type immune response and control the primary and secondary infection [30][31][32]. However data from C57BL/6 mice clearly shed light on CD8 + T-cells as contributors to CL control.…”

Section: Humoral Immune Response Evaluation By Elisa As Th1/th2 Deviamentioning

confidence: 99%

Assessment of Protection Induced by DNA and Live Vaccine Encoding Leishmania MHC Class I Restricted Epitopes against L. major Challenge in Balb/c Mice Model

Zandieh¹,

Kashi²,

Taheri³

2015

J Microb Biochem Technol

View full text Add to dashboard Cite

“…At the onset of a primary infection with L. major, parasites multiply at the site of infection, and lymphocytes from infected mice produce IFN-␥, IL-10, IL-4, and IL-13, clearly indicating no obvious bias toward Th1 or Th2 immunity. Mice infected with very low doses of parasites never develop cutaneous lesions, and these mice do not become immune to subsequent infection, indicating that lesion development plays an important role in the acquisition by BALB/c mice of what is termed "concomitant immunity" (14).…”

Section: Cr3mentioning

confidence: 99%

Complement Receptor 3 Deficiency Influences Lesion Progression duringLeishmania majorInfection in BALB/c Mice

et al. 2009

View full text Add to dashboard Cite

Leishmania major is an obligately intracellular protozoan parasite that causes cutaneous leishmaniasis. Like numerous intracellular pathogens, Leishmania exploits cell surface receptors as a means of entry into host cells. Complement receptor 3 (CR3; also called CD11b/CD18), a ␤ 2 integrin on phagocytic cells, is one such receptor. Ligation of CR3 has been shown to inhibit the production of interleukin-12, the cytokine that is pivotal in establishing the cell-mediated response necessary to combat intracellular infection. Here we investigate the role that CR3 plays in the establishment and progression of cutaneous leishmaniaisis in vivo. Dermal lesions of wild-type BALB/c mice are characteristically progressive and lead to extensive tissue necrosis coupled with elevated parasite burdens; CD11b-deficient BALB/c mice, however, demonstrate an intermediate phenotype characterized by chronic lesions and a reduced incidence of tissue damage. Infection followed by a reinfection challenge indicates that both susceptible (BALB/c) and resistant (C57BL/6) mice, regardless of CD11b status, develop resistance to L. major. In addition, CD11b does not bias the T helper cytokine response to L. major infection. Our results further indicate that CD11b is not necessary for disease resolution in resistant mice; rather, this protein appears to play a minor role in susceptibility.Leishmania species are a group of intracellular protozoan parasites that infect cells of the monocyte/macrophage lineage. These parasites cause a range of clinical manifestations, from localized, self-limiting cutaneous lesions to systemic fatal infections. Approximately 350 million people are at risk of infection worldwide (3), and an estimated 2 million new infections occur annually (16).Leishmania entry into host cells is receptor mediated. Leishmania parasites have been shown to engage Fc receptors (FcR) (62), mannose receptor (8), Toll-like receptors 2, 3 (24), and 4 (37), and complement receptor 3 (CR3; also called Mac-1 or ␣ M ␤ 2 ) (46); however, the interactions of Leishmania parasites with CR3 have been the best characterized. CR3 is a versatile leukocyte-associated receptor with a number of endogenous and pathogen-associated ligands; as a result, this protein has multiple functions, playing roles in immunity, adhesion, and cell migration (21). Such versatility is a reflection of the structure of CR3 as a heterodimer of CD11b and CD18. Most ligands interact with the CD11b chain lectin and I domains, which recognize mainly pathogen-associated molecules (21) and endogenous ligands (33), respectively. The ligand binding promiscuity of CR3 includes extracellular matrix proteins (63), ICAM-1 (40), and bacterial lipopolysaccharide (LPS) (42). The best-defined function of CR3 is its role as the receptor for C3bi, a complement component protein (35). Interestingly, the predominant Leishmania surface molecule lipophosphoglycan is readily opsonized by complement (17) and binds to CR3 directly (58). Although CR3 is present on the very cells that are meant to c...

show abstract

Intradermal inoculations of low doses of Leishmania major and Leishmania amazonensis metacyclic promastigotes induce different immunoparasitic processes and status of protection in BALB/c mice

Cited by 42 publications

References 54 publications

Real-Time In Vivo Green Fluorescent Protein Imaging of a Murine Leishmaniasis Model as a New Tool for Leishmania Vaccine and Drug Discovery

Real-Time In Vivo Green Fluorescent Protein Imaging of a Murine Leishmaniasis Model as a New Tool for Leishmania Vaccine and Drug Discovery

Assessment of Protection Induced by DNA and Live Vaccine Encoding Leishmania MHC Class I Restricted Epitopes against L. major Challenge in Balb/c Mice Model

Complement Receptor 3 Deficiency Influences Lesion Progression duringLeishmania majorInfection in BALB/c Mice

Contact Info

Product

Resources

About